Chovel-Sella Aluma, Karplus Rebekah, Sella Tal, Amital Howard
Department of Medicine B, Sheba Medical Center, Tel Hashomer, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Isr Med Assoc J. 2012 Jun;14(6):390-4.
Golimumab is a fully human monoclonal antibody targeting tumor necrosis factor-alpha (TNFalpha), an important cytokine in the pathogenesis of rheumatoid arthritis (RA) and other arthritides. Golimumab was approved for the treatment of rheumatoid arthritis with methotrexate (MTX) and with or without MTX for psoriatic arthritis and ankylosing spondylitis. Administration is by monthly subcutaneous injection. In this review we present some of the major clinical trials evaluating the efficacy of golimumab with or without concomitant MTX in RA patients, including patients resistant to previous biologic treatments. In addition, we collected data on safety and adverse effects encountered in clinical trials. Current data show golimumab to be an effective and safe choice for the treatment of various inflammatory arthritides.
戈利木单抗是一种全人源单克隆抗体，可靶向肿瘤坏死因子-α（TNFα），TNFα是类风湿关节炎（RA）和其他关节炎发病机制中的一种重要细胞因子。戈利木单抗被批准用于联合甲氨蝶呤（MTX）治疗类风湿关节炎，以及用于治疗银屑病关节炎和强直性脊柱炎，可联合或不联合MTX。给药方式为每月皮下注射。在本综述中，我们介绍了一些主要的临床试验，这些试验评估了戈利木单抗在类风湿关节炎患者中联合或不联合MTX的疗效，包括对先前生物治疗耐药的患者。此外，我们收集了临床试验中遇到的安全性和不良反应数据。目前的数据表明，戈利木单抗是治疗各种炎性关节炎的有效且安全的选择。
